PostEra vs Anterior
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF AI medicinal chemistry platform with $1B+ pharma partnerships; $610M Pfizer expansion Jan 2025 ($12M upfront) hitting preclinical milestones 40% faster; $26M raised competing with Schrödinger for AI small molecule and ADC drug design.
About
PostEra is a San Francisco-based AI-powered medicinal chemistry and drug discovery platform — backed with $26 million in total funding — providing pharmaceutical companies with the Proton AI platform for designing new small molecules and antibody-drug conjugates (ADCs) that accelerates the design-make-test cycle in drug discovery through machine learning models trained on medicinal chemistry synthesis rules and structure-activity relationships. PostEra has secured over $1 billion in total AI drug discovery partnerships including a $610 million collaboration expansion with Pfizer in January 2025 ($12 million upfront payment plus milestone payments and tiered royalties), and a partnership with Amgen and NIH. In the Pfizer collaboration, PostEra hit preclinical development milestones 40% faster than Pfizer anticipated, validating the AI acceleration thesis at pharmaceutical scale.
London and New York AI platform automating insurance prior authorization; reads patient clinical records to extract evidence justifying medical necessity and cut treatment delays.
About
Anterior is a London and New York-based healthtech company that applies AI to automate the prior authorization process, one of the most burdensome administrative tasks in U.S. healthcare. Prior authorization requires physicians to submit clinical evidence to insurance companies justifying the medical necessity of treatments, procedures, or medications — a process that consumes significant physician and staff time and causes treatment delays that harm patient outcomes. Anterior's AI reads patient clinical records, identifies the relevant clinical criteria required by the insurer, extracts supporting evidence from the patient's history, and generates complete prior auth submissions automatically. The platform also predicts approval likelihood and flags cases likely to require clinical review, helping health system staff prioritize their work. Founded in 2022, Anterior raised funding from investors including Sequoia Capital and has rapidly signed health system customers facing acute prior authorization burdens. The company's approach addresses a systemically inefficient process that costs the U.S. healthcare system an estimated $35B annually in administrative waste.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.